Comparative Pharmacology
Head-to-head clinical analysis: POHERDY versus TRIDESILON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POHERDY versus TRIDESILON.
POHERDY vs TRIDESILON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
POHERDY is a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2), binding to domain IV of the extracellular segment, thereby inhibiting ligand-independent HER2 signaling and mediating antibody-dependent cellular cytotoxicity (ADCC).
Desonide is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It acts by inducing phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of arachidonic acid from membrane phospholipids.
POHERDY: No approved drug. No dosing available.
0.05% ointment or cream applied topically to affected area twice daily.
None Documented
None Documented
Terminal half-life 12–18 hours (mean 15 h); requires dose adjustment in renal impairment (CrCl <30 mL/min)
2–3 hours (topical); 1–2 hours (systemic) after IV, with clinical duration prolonged due to tissue binding.
Renal: 60% unchanged; fecal/biliary: 30%; 10% metabolized
Primarily hepatic metabolism; metabolites excreted renally (70%) and in feces (30%).
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid